Canaccord Genuity Upgrades Global Blood Therapeutics (GBT) to Buy
Tweet Send to a Friend
Canaccord Genuity analyst John Newman upgraded Global Blood Therapeutics (NASDAQ: GBT) from ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
